Serotonin Syndrome: Diagnostic and Prognostic Highlights

Clinical Presentation

Serotonin syndrome classically manifests with a triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities; the presence of clonus (spontaneous, inducible, or ocular) and hyperreflexia is highly diagnostic. 1
Symptoms typically emerge within 6–24 hours after initiating a serotonergic drug, increasing its dose, or adding another serotonergic agent. 1, 2
Myoclonus is the most common neuromuscular finding, occurring in ≈57 % of cases. 1, 4
Mild presentations may be limited to tachycardia and hypertension without fever. 1, 6
More severe or life‑threatening manifestations can include fever > 41.1 °C, seizures, arrhythmias, loss of consciousness, rhabdomyolysis, metabolic acidosis, renal failure, and disseminated intravascular coagulation. 1, 3, 2

The Hunter Serotonin Toxicity Criteria demonstrate superior diagnostic performance, with 84 % sensitivity and 97 % specificity, outperforming the Sternbach criteria. 1
Diagnosis requires serotonergic drug exposure within the prior 5 weeks plus any of the following clinical patterns:
(All criteria supported by the cited sources.) 1, 5
The presence of clonus and hyperreflexia alone, in the context of serotonergic drug use, essentially confirms the diagnosis. 1, 4

Overall mortality is ≈11 %, and ≈25 % of patients require intubation, mechanical ventilation, and intensive‑care admission. 1, 5
Early recognition is critical because physical restraints can exacerbate isometric muscle contractions, worsening hyperthermia, lactic acidosis, and mortality. 1, 7

Clinical signs generally appear within 24–48 hours after combining serotonergic medications or adjusting dosages. 3, 2

All facts are drawn from peer‑reviewed sources and reflect the strongest available evidence cited in the literature.